Quemliclustat

Small molecule

Phase 3underway

Evidence outlook · registrational

Pancreatic Ductal Adenocarcinoma: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2030-11-30.

Company guidance: data expected first half of 2027 (Arcus Biosciences, 5 May 2026). “Results from this study are expected in the first half of 2027” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Pancreatic Ductal Adenocarcinoma
Phase 2 (5)
Pancreatic Ductal Adenocarcinoma
NCT06048484 · Gulam Manji
2024-05-10 – 2027-04 · Pancreatic Ductal Adenocarcinoma
What this study did
Other / comorbidity
NCT05915442 · Catherine Spina
2023-07-01 – 2028-12 · Oligometastatic Prostate Cancer
What this study did
NCT05676931 · Gilead Sciences
2023-02-21 – 2027-12 · Advanced Non-Small Cell Lung Cancer
What this study did
NCT06048133 · Nataliya Uboha
2024-03-08 – 2027-07 · Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
What this study did
NCT05329766 · Arcus Biosciences, Inc.
2022-06-10 – 2026-09-07 · Gastrointestinal Tract Malignancies
What this study did
Phase 1/2 (4)
Pancreatic Ductal Adenocarcinoma
NCT05688215 · Jonsson Comprehensive Cancer Center
2023-03-07 – 2028-12-31 · Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
What this study did
Other / comorbidity
NCT07667335 · Fred Hutchinson Cancer Center
2026-10-20 – 2029-07-16 · Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
What this study did
NCT04660812 · Arcus Biosciences, Inc.
2021-05-10 – 2025-09-05 · Metastatic Colorectal Cancer
What this study did
NCT04381832 · Arcus Biosciences, Inc.
2020-07-07 – 2024-08-30 · Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant
What this study did
Phase 1 (4)
Other / comorbidity
NCT04104672 · Arcus Biosciences, Inc.
2019-11-06 – 2026-07-21 · Advanced Pancreatic Cancer
What this study did
NCT07364214 · Arcus Biosciences, Inc.
2026-02-03 – 2026-04-06 · Healthy Participants
What this study did
NCT04575311 · Arcus Biosciences, Inc.
2020-10-20 – 2021-09-22 · Healthy Volunteers
What this study did
NCT03677973 · Arcus Biosciences, Inc.
2018-10-16 – 2019-08-19 · Healthy Volunteers
What this study did

Competitive landscape

This drug's own stage for Pancreatic Ductal Adenocarcinoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Quemliclustat: this drugPhase 3Small moleculeCD73 (NT5E)not yet gradedNo reviewed efficacy summary in this indication
Daraxonrasib (Rasonque)ApprovedSmall moleculepan-RAS, RAS (pan-RAS, RAS-mutant tumors)Partial signalNo reviewed efficacy summary in this indication
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)not yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
INCB161734Phase 3Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
SetidegrasibPhase 3Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
NavlimetostatPhase 2/3Small moleculePRMT5 (protein arginine methyltransferase 5), MTA-cooperative bindingnot yet gradedNo reviewed efficacy summary in this indication
Autogene CevumeranPhase 2Vaccine—not yet gradedNo reviewed efficacy summary in this indication
ERAS-0015Phase 2Small moleculepan-RASnot yet gradedNo reviewed efficacy summary in this indication
GFH375Phase 2Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
Nuzefatide PevedotinPhase 2PeptideEphA2not yet gradedNo reviewed efficacy summary in this indication
ARV-806
Phase 1/2(overall)
Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
VopimetostatPhase 1/2Small moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication
HSK41959
Phase 1(overall)
Small moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Quemliclustat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 2Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct CancerActive not recruiting
Est. primary completion 2026-12 · NCT06048133 · CT.gov ↗
What to watch
Phase 2Oligometastatic Prostate CancerRecruiting
Est. primary completion 2026-12-01 · NCT05915442 · CT.gov ↗
What to watch
2027 (3)
April 2027 (1)
Phase 2Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2027-04 · NCT06048484 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2Advanced Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12 · NCT05676931 · CT.gov ↗
What to watch
Phase 1/2Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT05688215 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
Phase 1/2Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma …Recruiting
Est. primary completion 2029-07-16 · NCT07667335 · CT.gov ↗
What to watch
2030 (1)
November 2030 (1)
Phase 3Pancreatic Ductal AdenocarcinomaActive not recruiting
Est. primary completion 2030-11-30 · NCT06608927 · CT.gov ↗
What to watch

See the full readout calendar ↗